Dilated Cardiomyopathy: From Genetics to Clinical Management
Open accessThe DOI matches its Crossref record; 605 of the 607 references it cites were found in a registry or an index, and 2 are not checked yet.
Abstract
This open access book presents a multidisciplinary comprehensive overview of dilated cardiomyopathy, from pathophysiology, differential diagnosis work-up, to clinical management. It further highlights open issues such as the clinical use of genetic testing and arrhythmia in dilated cardiomyopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Bolli, R., Chugh, A. R., D'Amario, D., Loughran, J. H., Stoddard, M. F., Ikram, S., Beache, G. M., Wagner, S. G., Leri, A., Hosoda, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61590-0 · Cited by 1,288
RetractedYaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Üstün, Y. E. (2019) · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · Cited by 169,581
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Another cell-based strategy involves the production and in vitro expansion of CMs from human embryonic stem cells or iPSCs [8].”
BackgroundMcDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., Flachskampf, F. A., Foster, E., Goldstein, S. A., Kuznetsova, T., et al. (2015) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.10.003 · Cited by 12,362
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Research works printed but not linked: 77
- [426]Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation. 2010;122:900-9.
- [428]Chimenti C, Frustaci A. Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28-year period. Circulation. 2013;128:1531-41.
- [435]Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013;128(16):e240-327.
- [437]Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Wojciechowska C, Glanowska G, Wilczewski P, et al. Randomized, placebo-controlled study for immunosuppressive treat- ment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104(1):39-45.
- [447]Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113:876-90.
- [448]Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocar- ditis. J Am Coll Cardiol. 2012;59:779-92.
- [454]Towbin JA, Lorts A. Arrhythmias and dilated cardiomyopathy common pathogenetic path- ways? J Am Coll Cardiol. 2011;57(21):2169-71.
- [478]Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-30.
- [482]Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2014;63(18):1879-89.
- [484]Arbustini E, Disertori M, Narula J. Primary prevention of sudden arrhythmic death in dilated cardiomyopathy current guidelines and risk stratification. JACC Heart Fail. 2017;5(1):39-43.
- [486]van Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. 2012;59(5):493-500.
- [487]Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease; a cause of reversible heart failure. Am J Med. 1949;7(4):478-89.
- [488]Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol. 1996;19(1):95-106.
- [489]Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol. 2015;66(15):1714-28.
- [493]Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation. 2016;133(17):1637-44.
- [494]Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-77.
- [497]Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol. 2006;48(11):2340-7.
- [498]Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008;118(24):2498-505.
- [500]Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417-27.
- [504]Packer DL, Prutkin JM, Hellkamp AS, Mitchell LB, Bernstein RC, Wood F, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120(22):2170-6.
- [506]Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of beta- blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. JAMA. 2006;295(2):165-71.
- [516]Nakahara S, Tung R, Ramirez RJ, Michowitz Y, Vaseghi M, Buch E, et al. Characterization of the arrhythmogenic substrate in ischemic and nonischemic cardiomyopathy implications for catheter ablation of hemodynamically unstable ventricular tachycardia. J Am Coll Cardiol. 2010;55(21):2355-65.
- [521]Dinov B, Fiedler L, Schönbauer R, Bollmann A, Rolf S, Piorkowski C, et al. Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy. Circulation. 2014;129:728-36.
- [522]Oloriz T, Silberbauer J, Maccabelli G, Mizuno H, Baratto F, Kirubakaran S, et al. Catheter ablation of ventricular arrhythmia in nonischemic cardiomyopathy: anteroseptal versus infero- lateral scar sub-types. Circ Arrhythm Electrophysiol. 2014;7(3):414-23.
- [523]Dinov B, Arya A, Schratter A, Schirripa V, Fiedler L, Sommer P, et al. Catheter ablation of ventricular tachycardia and mortality in patients with nonischemic dilated cardiomyopathy: can noninducibility after ablation be a predictor for reduced mortality? Circ Arrhythm Electrophysiol. 2015;8(3):598-605.
- [524]Yu R, Ma S, Tung R, Stevens S, Macias C, Bradfield J, et al. Catheter ablation of scar-based ventricular tachycardia: relationship of procedure duration to outcomes and hospital mortality. Heart Rhythm. 2015;12(1):86-94.
- [525]Gökoğlan Y, Mohanty S, Gianni C, Santangeli P, Trivedi C, Güneş MF, et al. Scar homog- enization versus limited-substrate ablation in patients with nonischemic cardiomyopathy and ventricular tachycardia. J Am Coll Cardiol. 2016;68(18):1990-8.
- [526]Santangeli P, Muser D, Zado ES, Magnani S, Khetpal S, Hutchinson MD, et al. Acute hemo- dynamic decompensation during catheter ablation of scar-related ventricular tachycardia: inci- dence, predictors, and impact on mortality. Circ Arrhythm Electrophysiol. 2015;8(1):68-75.
- [527]Muser D, Liang JJ, Castro SA, Hayashi T, Enriquez A, Troutman GS, et al. Outcomes with prophylactic use of percutaneous left ventricular assist devices in high-risk patients undergo- ing catheter ablation of scar-related ventricular tachycardia: a propensity-matched analysis. Heart Rhythm. 2018;15(10):1500-6.
- [529]Piers SR, Tao Q, van Huls van Taxis CF, Schalij MJ, van der Geest RJ, Zeppenfeld K. Contrast- enhanced MRI-derived scar patterns and associated ventricular tachycardias in nonisch- emic cardiomyopathy: implications for the ablation strategy. Circ Arrhythm Electrophysiol. 2013;6(5):875-83.
- [530]Hayashi T, Santangeli P, Pathak RK, Muser D, Liang JJ, Castro SA, et al. Outcomes of catheter ablation of idiopathic outflow tract ventricular arrhythmias with an R wave pattern break in lead V2: a distinct clinical entity. J Cardiovasc Electrophysiol. 2017;28(5):504-14.
- [531]Berruezo A, Mont L, Nava S, Chueca E, Bartholomay E, Brugada J. Electrocardiographic rec- ognition of the epicardial origin of ventricular tachycardias. Circulation. 2004;109(15):1842-7.
- [532]Shun-Shin MJ, Zheng SL, Cole GD, Howard JP, Whinnett ZI, Francis DP. Implantable car- dioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials. Eur Heart J. 2017;38(22):1738-46.
- [571]Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prog- nostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011;57:1468-76. https://doi.org/10.1016/j. jacc.2010.11.030. · doi:10.1016/j
- [604]Sinagra G, Anzini M, Pereira NL, Bussani R, Finocchiaro G, Bartunek J, et al. Myocarditis in clinical practice. Mayo Clin Proc. 2016;91(9):1256-66. https://doi.org/10.1016/j. mayocp.2016.05.013. · doi:10.1016/j
- [653]Maron BJ, Shirani J, Poliac LC, Mathenge R, Roberts WC, Mueller FO. Sudden death in young competitive athletes. JAMA. 1996;276(3):199.
- [658]Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, et al. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007;115(12):1643-455.
- [667]Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guide- lines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. https://doi.org/10.1093/eurheartj/ ehw128. · doi:10.1093/eurheartj/
- [677]McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin- neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. https://doi.org/10.1056/NEJMoa1409077. · DOI · Paper page
- [687]Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al. Prophylactic defi- brillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-8.
- [689]Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator implanta- tion in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-30. https://doi.org/10.1056/NEJMoa1608029. · DOI · Paper page
- [692]Iuliano S, Fisher SG, Karasik PE, Fletcher RD, Singh SN. Department of Veterans Affairs Survival Trial of antiarrhythmic therapy in congestive heart failure. QRS duration and mortal- ity in patients with congestive heart failure. Am Heart J. 2002;143(6):1085-91.
- [706]Stolfo D, Merlo M, Pinamonti B, Poli S, Gigli M, Barbati G, et al. Early improvement of func- tional mitral regurgitation in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2015;115(8):1137-43. https://doi.org/10.1016/j.amjcard.2015.01.549. · DOI
- [718]Merlo M, Anzini M, Bussani R, Artico J, Barbati G, Stolfo D, et al. Characterization and long- term prognosis of postmyocarditic dilated cardiomyopathy compared with idiopathic dilated cardiomyopathy. Am J Cardiol. 2016;118:895-900.
- [726]Priori SG, Blomström-Lundqvist C, Mazzanti A. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;8:746-837.
- [728]Dal Ferro M, Stolfo D, Altinier A, Gigli M, Perrieri M, Ramani F, et al. Association between mutation status and left ventricular reverse remodelling in dilated cardiomyopathy. Heart. 2017;103:1704-10.
- [735]Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531-47.
- [736]Menon SC, Michels VV, Pellikka PA, Ballew JD, Karst ML, Herron KJ, et al. Cardiac troponin T mutation in familial cardiomyopathy with variable remodeling and restrictive physiology. Clin Genet. 2008;74:445-54.
- [737]Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing risk stratification for sud- den death in dilated cardiomyopathy. Circulation. 2017;136:215-31.
- [740]Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycar- dia-AMIOVIRT. J Am Coll Cardiol. 2003;41:1707-12.
- [741]Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al. Prophylactic defibril- lator implantation in patients with nonischemic dilated cardiomyopathy for the defibrillators in non-ischemic cardiomyopathy treatment evaluation (DEFINITE) investigators. N Engl J Med. 2004;350:2151-8.
- [742]Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implant- able cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-37.
- [743]Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221-30.
- [745]Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JGF, et al. Prediction of mode of death in heart failure: the Seattle heart failure model. Circulation. 2007;116:392-8.
- [747]Spezzacatene A, Sinagra G, Merlo M, Barbati G, Graw SL, Brun F, et al. Arrhythmogenic phe- notype in dilated cardiomyopathy: natural history and predictors of life-threatening arrhyth- mias. J Am Heart Assoc. 2015;4:e002149.
- [750]Van Rijsingen IAW, Van Der Zwaag PA, Groeneweg JA, Nannenberg EA, Jongbloed JDH, Zwinderman AH, et al. Outcome in phospholamban R14del carriers results of a large multi- centre cohort study. Circ Cardiovasc Genet. 2014;7:455-65.
- [754]Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896-908.
- [755]Di Marco A, Anguera I, Schmitt M, Klem I, Neilan T, White JA, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopa- thy: systematic review and meta-analysis. JACC Heart Fail. 2017;5:28-38.
- [758]Merlo M, Gobbo M, Stolfo D, Losurdo P, Ramani F, Barbati G, et al. The prognostic impact of the evolution of RV function in idiopathic DCM. JACC Cardiovasc Imaging. 2016;9:1034-42.
- [760]Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol. 2014;63:1879-89.
- [761]Zecchin M, Merlo M, Pivetta A, Barbati G, Lutman C, Gregori D, et al. How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with "SCD-HeFT criteria?". Am J Cardiol. 2012;109:729-35.
- [762]Losurdo P, Stolfo D, Merlo M, Barbati G, Gobbo M, Gigli M, et al. Early arrhythmic events in idiopathic dilated cardiomyopathy. JACC Clin Electrophysiol. 2016;2:535-43.
- [763]Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, et al. Use of the wear- able cardioverter defibrillator in high-risk cardiac patients data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II registry). Circulation. 2015;132:1613-9.
- [765]Merlo M, Pivetta A, Pinamonti B, Stolfo D, Zecchin M, Barbati G, et al. Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years. Eur J Heart Fail. 2014;16:317-24.
- [766]McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin- neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
- [768]Hare JM, DiFede DL, Castellanos AM, Florea V, Landin AM, El-Khorazaty J, et al. Randomized comparison of allogeneic vs. autologous mesenchymal stem cells for non-ischemic dilated car- diomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017;69:526-37.
- [769]Woitek F, Zentilin L, Hoffman NE, Powers JC, Ottiger I, Parikh S, et al. Intracoronary cyto- protective gene therapy: a study of VEGF-B167 in a pre-clinical animal model of dilated car- diomyopathy. J Am Coll Cardiol. 2015;66:139-53.
- [771]Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67:2996-3010.
- [775]Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-24.
- [781]Pérez-Molina JA, Molina I. Chagas disease. Lancet. 2018;391:82-94.
- [783]de Andrade JP, Marin Neto JA, de Paola AAV, Vilas-Boas F, Oliveira GMM, Bacal F, et al. I Latin American guidelines for the diagnosis and treatment of Chagas' heart disease: executive summary. Arq Bras Cardiol. 2011;96:434-42.
- [784]Rassi A, Rassi A, Rassi SG. Predictors of mortality in chronic Chagas disease. Circulation. 2007;115:1101-9.
- [785]Fish AE, Pride YB, Pinto DS. Lyme carditis. Infect Dis Clin North Am. 2008;22:275-88.
- [800]Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopa- thy. N Engl J Med. 2000;342:1077-84.
- [801]Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 European Society of Cardiology position paper on cancer treatments and cardiovas- cular toxicity. Eur Heart J. 2016;37:2768-801.
- [804]Ware JS, Amor-salamanca A, Tayal U, Govind R, Serrano I, Pascual-figal DA, et al. Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol. 2018;71:2293-302.
- [811]Guzzo-Merello G, Cobo-Marcos M, Gallego-Delgado M, Garcia-Pavia P. Alcoholic cardio- myopathy. World J Cardiol. 2014;6:771-81.
Cited by
Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments
Orphanou, N., Papatheodorou, E., & Anastasakis, A. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10139-0 · Cited by 137
Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity
Cullen, M. R., Lemeshow, A. R., Russo, L., Barnes, D. M., Ababio, Y., & Habtezion, A. (2022) · Healthcare · doi:10.3390/healthcare10040603 · Cited by 59
Inherited Arrhythmias in the Pediatric Population: An Updated Overview
Mariani, M. V., Pierucci, N., Fanisio, F., Laviola, D., Silvetti, G., Piro, A., Fazia, V. M. L., Chimenti, C., Rebecchi, M., Drago, F., et al. (2024) · Medicina · doi:10.3390/medicina60010094 · Cited by 46
“VA is infrequently found to be the root of HF in children [110].”
BackgroundRisk stratification in cardiomyopathy
Sinagra, G., Carriere, C., Clemenza, F., Minà, C., Bandera, F., Zaffalon, D., Gugliandolo, P., Merlo, M., Guazzi, M., & Agostoni, P. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320961898 · Cited by 37
Self-citationDilated cardiomyopathy: a new insight into the rare but common cause of heart failure
Giri, P., Mukhopadhyay, A., Gupta, M., & Mohapatra, B. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10125-6 · Cited by 33
Metadata
- Authors
- Sinagra, G., Merlo, M., & Pinamonti, B.
- Affiliations
- Azienda Sanitaria Universitaria Integrata di Trieste (IT)
- ORCID
- Gianfranco Sinagra
- Venue
- Springer eBooks
- Publisher
- Springer International Publishing
- Published
- 2019
- OpenAlex
- W4313642785
- Cited by
- 32
- References
- 603
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 9 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 2
- FWCI
- 5.48
- Type
- book
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Springer eBooks (publishedVersion, cc-by)
- ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, cc-by)
- Directory of Open access Books (OAPEN Foundation) (submittedVersion, cc-by)
- Funders
- ACRC - Associazione Culturale per la Ricerca in Cardioscienze
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- dilated cardiomyopathy, pathophysiology, differential diagnosis, clinical management, genetic testing, cardiac arrhythmias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dilated Cardiomyopathy: From Genetics to Clinical Management. https://app.cochat.ai/papers/10.1007/978-3-030-13864-6
- The paper
- Sinagra, G., Merlo, M., & Pinamonti, B. (2019). Dilated Cardiomyopathy: From Genetics to Clinical Management. Springer eBooks. https://doi.org/10.1007/978-3-030-13864-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.